The leukotrienes: Mediators of chronic inflammation in asthma

Clinical and Experimental Allergy

Volumn 26, Issue 9, 1996, Pages 995-1004

  Sampson, A P ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; APAFANT; ARACHIDONATE 5 LIPOXYGENASE; ATROPINE; BRONCHODILATING AGENT; FOROPAFANT; IPRATROPIUM BROMIDE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; POBILUKAST; PRANLUKAST; THEOPHYLLINE; TOMELUKAST; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHOSPASM; CHEMOTAXIS; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029792615     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.1996.tb00639.x     Document Type: Review

References (103)

1. Arm JP, Lee TH. Sulphidopeptide leukotrienes in asthma. Clin Sci 1993; 84:501-10.
2. Dixon RA, Diehl RE, Opas E et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343:282-4
3. Morris HR, Taylor GW, Piper PJ, Tippins JR. Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature 1980; 285:104-7
4. 4 and leukotriene D. Pharmacol Exp Ther 1986; 237:558-62.
5. Dahlén S-E. Leukotrienes as mediators of airway obstruction and bronchial hyperresponsiveness. In: Page C, Gardiner PJ, eds. Airway hyperresponsiveness: is it really important? Oxford: Blackwell Science, 1993: 180-205.
6. Holroyde MC, Altounyan REC, Cole M, Dixon M, Elliott EV. Bronchoconstriction produced in man by leukotrienes C and D. Lancet 1981; ii:17-8.
7. 4 in normal and asthmatic subjects. Am Rev Respir Dis 1987; 135:333-7.
8. 4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins 1983; 25:155-70.
9. Bisgaard H, Pedersen M. SRS-A leukotrienes decrease the activity of human respiratory cilia. Clin Allergy 1987; 17:95-103.
10. Ahmed T, Greenblatt DW, Birch S, Marchette B, Wanner A. Abnormal mucociliary transport in allergic patients with antigen-induced bronchospasm: role of slow-reacting substance of anaphylaxis. AmRev Respir Dis 1981; 124:110-4.
11. 4. Am J Pathol 1987; 126:19-24.
12. Woodward DE, Weichman BM, Gill CA, Wasserman MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983; 25:131-42.
13. Obata T, Kobayashi T, Okada Y et al. Effect of a peptide leukotriene antagonist ONO-1078 on antigen-induced airway microvascular permeability in actively sensitised guinea-pigs. Life Sci 1992; 51:1577-83.
14. 4 receptor antagonist ICI 204-219. Am Rev Respir Dis 1990; 141:988-92.
15. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; i: 584-8.
16. 4 receptor antagonist, MK-571, Ann NYAcad Sci 1991; 629:436.
17. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI;204:219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89:1040-5.
18. Diamant Z, Timmers MC, Van der Veen H et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95:42-51.
19. Taniguchi Y, Tamura G, Honma M et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92:507-12.
20. Bjorck T, Dahlen SE. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulm Pharmacol 1993; 6:87-96.
21. 4 antagonist. N Engl J Med 1990; 323:1736-9.
22. 4 receptor antagonist ICI;204:219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147:1413-8.
23. 4 receptor antagonist ICI;204:219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147:1431-5.
24. Spector SL, Glass M, Minkwitz MC. The effect of six weeks of therapy with oral doses of ICI;204:219 in asthmatics. Am Rev Respir Dis 1992; 145: A16.
25. 4, in chronic asthma. Am Rev Respir Dis 1992; 145: A16.
26. Liu M, Cohn J, Zileuton Study Group. Effects of zileuton, a 5-lipoxygenase inhibitor, in moderate asthma: results of a 6-month double-blind placebo-controlled trial. Eur Respir J 1994; 7:282 s.
27. Israel E, Cohn J, Dube L, Drazen J, Zileuton Study Group. Chronic 5-lipoxygenase (5-LO) inhibition by zileuton significantly decreases the requirement for acute steroid treatment of asthma. Am J Respir Crit Care Med 1995; 151: A678.
28. Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 81:711-7.
29. 4 in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84:19-26.
30. Wenzel SE, Westcott JY, Larsen GL. Bronchoalveolar lavage fluid mediator levels 5 min after allergen challenge in atopic subjects with asthma. Relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991; 87:540-8.
31. Crea AE, Nakhosteen JA, Lee TH. Mediator concentrations in bronchoalveolar lavage fluid of patients with mild asymptomatic bronchial asthma. Eur Respir J 1992; 5:190-5.
32. 4 elimination and metabolism in man. J Allergy Clin Immunol 1990; 85:3-9.
33. Sampson AP, Castling DP, Green CP, Price JF. Persistent elevation in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 1995; 72:221-5.
34. 4 and lung function in cystic fibrosis children. Br J Clin Pharmacol 1993; 36:494P-495P.
35. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143:1025-9.
36. 4 in bronchial asthma. Eur Respir J 1992; 5:693-9.
37. 4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990; 86:211-20.
38. 4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989; 140:148-53.
39. Israel E, Rubin P, Kemp JP et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059-66.
40. Schwartz HJ, Petty T, Reed R, Dube LM, Swanson LJ, and Zileuton Study Group. The comparative effects of zileuton, a 5-lipoxygenase inhibitor, vs theophylline in patients with moderate asthma: results from a 13-week, multicenter trial. Am J Respir Crit Care Med 1995; 151: A376.
41. 4) antagonist in mild to moderate asthma. J Allergy Clin Immunol 1990; 85: A197.
42. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992; 146:358-63.
43. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl leukotriene antagonist. Lancet 1991; 337:1062-3.
44. Wilkens H, Wilkens JH, Busse S et al. Effects of an inhaled PAF-antagonist (WEB 2086) on allergen-induced early and late asthmatic responses and increased bronchial responsiveness to methacholine. Am Rev Respir Dis 1991; 143: A812.
45. O'Connor BJ, Evans DJ, Coulby LJ, Cluzel M. Attenuation of the late asthmatic response following treatment with a PAF receptor antagonist, SR27417 A. Eur Respir J 1995; 8:377 s.
46. 1-receptor blockade on the development of early and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma. J Allergy Clin Immunol 1993; 91:1169-78.
47. 1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993; 91:1005-14.
48. Kohno S, Tsuzuike N, Yamamura H et al. Important role of peptide leukotrienes (p-LTs) in the resting tonus of isolated human bronchi. Jpn J Pharmacol 1993; 62:351-5.
49. 4-induced airway hyperresponsiveness of guinea-pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci USA 1984; 81:4922-5.
50. 4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990; 141:993-7.
51. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988; 82:654-60.
52. 4-induced histamine hyperresponsiveness in asthmatic subjects. Am Rev Respir Dis 1992; 146:1506-10.
53. 2 receptor antagonist on bronchial hyperresponsiveness to methacholine in subjects with asthma. J Allergy Clin Immunol 1991; 87:23-7.
54. 4, methacholine, or histamine. Am Rev Respir Dis 1990; 142:1112-8.
55. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of the cysteinyl-leukotriene receptor antagonist ICI;204:219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:690-4.
56. Fujimura M, Sakamoto S, Kamis Y, Matsuda T. Effect of a leukotriene antagonist ONO 1078 on bronchial hyperresponsiveness in patients with asthma. Resp Med 1993; 87:133-8.
57. Taki F, Suzuki R, Torii K et al. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4- (4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)- 4H-1-benzopyran hemihydrate. Arzneimittelforschung 1944; 44:330.
58. Barnes NC, Piper PJ, Costello JF. Actions of inhaled leukotrienes and their interactions with other allergic mediators. Prostaglandins 1984; 28:629-30.
59. 4 in allergen- induced increases in airway smooth muscle in the rat. Am Rev Respir Dis 1993; 148:413-7.
60. Leikauf GD, Claesson HE, Doupnik CA, Hybbinette S, Grafstrom RC. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am J Physiol 1990; 259: L255-L261.
61. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH. Leukotriene B: a potent chemotactic and aggregating substance released from polymorphonuclear leucocytes. Nature 1980; 286:264-5.
62. 4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994; 55:183-91.
63. Chan CC, McKee K, Tagari P, Chee P, Ford-Hutchinson AW. Eosinophil eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist. Eur J Pharmacol 1990; 191:273-80.
64. Hay DWP, Torphy TP, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16:304-9.
65. Foster A, Chan CC. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitised guinea-pig. Int Arch Allergy Appl Immunol 1991; 96:279-84.
66. 4 receptor antagonism reduces airway hyperresponsiveness in monkeys. Pulm Pharmacol 1994; 7:49-58.
67. Abraham WM, Ahmed A, Cortes A et al. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep. Eur J Pharmacol 1992; 217:119-26.
68. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341:989-90.
69. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma. Am J Respir Crit Care Med 1995; 151: A42.
70. Wenzel SE, Trudeau JB, Kaminsky DA et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma Am J Respir Crit Care Med 1995; 152:897-05.
71. Haley K, Sunday M, Reilly J et al. Immunolocalization of five lipoxygenase activating protein and five lipoxygenase in normal and asthmatic lung. Am J Respir Crit Care Med 1995; 151: A677.
72. Damon M, Chavis C, Crastes de Paulet A, Michel FB, Godard PG. Arachidonic acid metabolism in alveolar macrophages: a comparison of cells from healthy subjects, allergic asthmatics, and chronic bronchitis patients. Prostaglandins 1987; 34:291-309.
73. 4 generation by bronchoalveolar lavage cells in asthma. Thorax 1995; 50:67-73.
74. 4 from eosinophils in asthmatic patients. Allergy 1985; 40:571-3.
75. Radeau T, Chavis C, Damon M et al. Enhanced arachidonic acid metabolism and human neutrophil migration in asthma. Prostaglandins Leukot Essent Fatty Acids 1990; 41:131-8.
76. Sampson AP, Thomas RU, Costello JF, Piper PJ. Enhanced leukotriene synthesis in leucocytes of atopic and asthmatic subjects. Br J Clin Pharmacol 1992; 33:423-30.
77. Redington AE, Bradding P, Holgate ST. The role of cytokines in the pathogenesis of allergic asthma. Rev Immunol 1993; 5:174-200.
78. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyle population in atopic asthma. N Engl J Med 1992; 326:298-304.
79. Owen WF, Rothenburg ME, Silberstein DS et al. Regulation of human eosinophil viability, density, and function by GM-CSF in the presence of 3T3 fibroblasts. J Exp Med 1987; 166:129-41.
80. Rothenberg ME, Owen WF, Silberstein DS et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin. Clin Invest 1988; 81:1986-92.
81. 4 in response to soluble agonists. J Immunol 1991; 147:3855-61.
82. 2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis. Proc Natl Acad Sci USA 1993; 90:4475-9.
83. 2 by phosphorylation in rat mesangial cells. J Clin Invest 1994; 93:1224-33.
84. De Valck D, Beyaert R, Van Roy F, Fiers W. Tumor necrosis factor cytotoxicity is associated with phospholipase D activation. Eur J Biochem 1993; 212:491-7.
85. 2. Arthritis Rheum 1994; 37:653-61.
86. Bourgoin S, Poubelle PE, Liao NW et al. Granulocyte-macrophage colony-stimulating factor primes phospholipase D activity in human neutrophils in vitro: role of calcium, G-proteins and tyrosine kinases. Cell Signal 1992; 4:487-500.
87. McDonald PP, Pouliot M, Borgeat P. Enhancement by GM-CSF of agonist-induced 5-lipoxygenase activation in human neutrophils involves protein synthesis and gene transcription. J Lipid Mediat 1993; 6:59-67.
88. Pouliot M, McDonald PP, Borgeat P, McColl SR. Granulocyte-macrophage colony stimulating factor stimulates the expression of the 5-lipoxygenase- activating protein (FLAP) in human neutrophils. J Exp Med 1994; 179: 12225-32.
89. Pouliot M, McDonald PP, Khamzina L, Borgeat P, McColl SR. Granulocyte-macrophage colony-stimulating factor enhances 5-lipoxygenase levels in human polymorphonuclear leucocytes. J Immunol 1994; 152:851-8.
90. Murakami M, Austen KF, Arm JP. Cytokine regulation of arachidonic acid metabolism in mast cells In: Kitamura Y, Yamamoto S, Galli SJ, Greaves MW, eds. Biological and molecular aspects of mast cell and basophil differentiation and function. New York: Raven Press, 1995:25-37.
91. Lepley RA, Fitzpatrick FA. 5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. J Biol Chem 1994; 269:24163-8.
92. Khan MA, Hoffbrand AV, Mehta A et al. MK 886, an antagonist of leukotriene generation, inhibits DNA synthesis in a subset of acute myeloid leukaemia cells. Leuk Res 1993; 17:759-62.
93. Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA. Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). J Biol Chem 1991; 266:8511-6.
94. Hoshiko S, Radmark O, Samuelsson B. Characterization of the human 5-lipoxygenase promoter. Proc Natl Acad Sci USA 1990; 87:9073-7.
95. 4 transcriptionally activates interleukin-6 expression involving NK-κB and NF-IL6. Eur J Immunol 1992; 22:2705-11.
96. 4 in human lymphocyte cultures. Prostag Leukot Med 1986; 23:207-10.
97. 4 induces interleukin 5 generation from human T lymphocytes. Eur J Immunol 1993; 23:2392-8.
98. 4 enhances IL-4-indueed IgE production from normal human lymphocytes. Cell Immunol 1994; 156:124-34
99. 4 stimulates human polymorphonuclear leucocytes to synthesize and release interleukin-8 in vitro. Am J Respir Cell Mol Biol 1994; 10:651-7.
100. 4 synthesis by a lipoxygenase inhibitor. J Leukoc Biol 1993; 54:269-74.
101. Covin RB, Baillie MB, Peters-Golden M. Changes in the subcellular distribution of 5-lipoxygcnase accompany macrophage differentiation in the lung. Am J Respir Crit Care Med 1995; 151: A677.
102. Brock TG, Paine R, Peters-Golden M. Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. J Biol Chem 1994; 269:22059-66.
103. Woods JW, Colley MJ, Singer J, Peters-Golden M. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope with cell activation. Am J Respir Crit Care Med 1994; 149: A97.